Factores de crescimento hematopoiético no cancro do pulmão

Chemoradiotherapy with or without Granulocyte - Macrophage Colony Stimulating Factor in the Treatment of Limited - Stage Small Cell Lung Cancer: a Prospective Phase III Randomized Study of the South West Oncology Group.

Clin. Oncol., 13 (1995), pp. 1632-1641

[9.]

S.T. Cwyer, K. Pentc.

Erythropoietin Cell Biology.

Hemat./Onc. Clin. N. Am, 8 (1994), pp. 895-911

[10.]

D. Cella.

Factors Influencing Quality of Life in Cancer Patients: Anemia and Fatigue.

Semin. Oncol., 25 (1998), pp. 43-46

Medline

[11.]

C. Chouaid, L. Bassinet, C. Fuhrman, I. Monnet, B. Housset.

Routine Use of Granulocyte Colony Stimulating Factor is not cost-effective and does not increase Patient Confort in the Treatment of Small - Cell Lung Cancer: An Analisys Using a Markou Model.

Clin. One., 16 (1998), pp. 2700-2707

[12.]

J. Crawford, H. Ozer, R. Stoller, et al.

Reduction by Granulocyte Colony Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer.

N. Engi. J. Meet., 325 (1991), pp. 164-170

[13.]

A.J. Croockewit, M.H. Broncheud, M.S. Aapro, et al.

A European Perspective on Haematopoietic Growth Factors in Haemato-Oncology: Report of an Expert Meeting of the EORTC.

Eur. J. Cancer., 33 (1997), pp. 1732-1746

Medline

[14.]

G.B. Demetri, M. Kris, J. Wade, et al.

Quality of Life Benefit in Chemotherapy Patients Treated with Epoietin Alfa is lndepedent of Disease Response or Tumor Type: Results from a Prespective Community Oncology Study.

J. Clin. Oncol, 16 (1998), pp. 3412-3425

http://dx.doi.org/10.1200/jco.1998.16.10.3412 | Medline

[15.]

S. Dische, M.I. Saunders.

Tumor Oxygenation in Cancer Therapy: Is it lmportant? Can it be lmproved?.

Rherytbropoietin in Cancer Supportive Treatment, pp. 241-251

[16.]

M. Engelhard, G. Brittinger.

Clinical relevance of Granulocyte - Macrophage Colony - Stimulating Factor.

Semin. Oncol., 21 (1994), pp. 1-4

Medline

[17.]

M. Fukuoka, N. Masuda, Negoros, et al.

CODE Chemotherapy with and without Granu.locyte Colony Stimulating factor in small cell lung Cancer.

Brit. J. Canc., 75 (1997), pp. 306-309

[18.]

K. Furuse, M. Fukuoka, et al.

Phase III Study of lntensive Weekly Chemoterapy with Recombinant Human Granulocyte Colony- Stimulating Factor versus Standard Chemotherapy in Extensive-Disease Small-Cell Lung Cancer.

J. Clin. Oncol., 16 (1998), pp. 2126-2132

http://dx.doi.org/10.1200/jco.1998.16.6.2126 | Medline

[19.]

D.J. Girljng, N. Thatcher, P.I. Clark, R.J. Stephen.

Increasing the Dose Intensity of Chemotherapy by means of Granulocyte-Colony Stimulating factor (G-CSF) Support in the Treatment of Small Cell Lung Cancer (SCLC).

Eur. J Cancer, 32 (1996), pp. 1263

[20.]

B. Glisson, R. Komakj, et al.

Integration of Filgrastim into Chemoradiation for Limited Small Cell Lung Cancer: A Phase I Study Int.

J. Rad. Oncol., Bioi. Phys, 40 (1998), pp. 331-336

[21.]

J.D. Griffin.

Hematopoietic growth factors.

Cancer, Principles and Practice of Oncology, 5, pp. 2639-2657

[22.]

J.T. Hamm, J. Schieller, C. Cuffies, et al.

Dose Ranging Study of Recombinant Human Granulocyte Macrophage Colony Stimulating Factor in Small Cell Lung Cancer.

J. Clin. Oncol., 12 (1994), pp. 2667-2676

http://dx.doi.org/10.1200/jco.1994.12.12.2667 | Medline

[23.]

D. Henry, R. Abels, K. Larhdt.

Prediction of Response to Recombinant Human Erythropoietin (R-HuEPO) Therapy in Cancer Patients.

Blood, 85 (1995), pp. 1676-1678

Medline

[24.]

D.H. Henry.

Recombinant Human Erythropoietin in the Treatment of the Anemia Associated with Solid Tumors.

Erythropoietin Molecular Physiology and clinical applications, pp. 293-298

[25.]

D.H. Henry.

Clinical Application of Recombinant Erythropoietin in Anemic Cancer Patients.

Hem. One. Clin. N. Am., 8 (1994), pp. 961-973

[26.]

R.S. Hillman.

Hematopoietic Agents, Goodman e Gilman's.

ThePharmacological Basis of Therapeutics, pp. 1311-1317

[27.]

T.R. Klumpp, K.F. Mangan, S.L. Goldberg, E.S. Pearl-Man, J.S. Macdonald.

Granulocyte Colony Stimulating Factor Accelerates Neutrophil Enfraftment Following Peripheral Blood Stem-cell Transplantation:A prospective, randomized trial.

Clin. Oncol., 13 (1995), pp. 1323-1327

[28.]

M.J. Koury.

Progress in Understanding Erythropoiesis.

Rherythropoietin in Cancer Supportive Treatment, pp. 1-12

[29.]

B. Lebeau.

Polémiques sur le Traitement des Cancers a Petites Cellules.

Rev. Mal. Resp., 13 (1996), pp. 84

[30.]

C. Leitgeb, M. Pecherstorfer, E. Fritz, et al.

Quality of Life in Chronic Anemia of Cancer During Treatment with Recombinant Human Erythropoietin.

Cancer, 73 (1994), pp. 2535-2542

Medline

[31.]

A.W. Lieschkeg BURGESS.

Granulocyte-Macrophage Colony-Stimulating Factor.

N. Eng. J. Med., 327 (1992), pp. 128-135

[32.]

H. Ludwig, E. Fritz.

Incidence and Clinical Significance of Anemia in Malignant Diseases.

Rherythropoietin in Cancer Supportive Treatment, pp. 35-44

[33.]

H. Ludwig, E. Sundal, M. Pecherstorfer.

Recombinant Human Erythropoietin for the Corrrection of Cancer Associated Anemia With and Without concomitant Cytotoxic Chemotherapy.

Cancer, 76 (1995), pp. 2319-2329

Medline

[34.]

H. Ludwig, E. Fritz, C. Leitgeb, et al.

Prediction of Response to Eritropoietin Treatment in Chronic Anemia of Cancer.

Blood, 84 (1994), pp. 1056-1063

Medline

[35.]

H. Ludwig, E. Fritz.

Anemia in Cancer Patients.

Semin. Oncol., 25 (1998), pp. 2-6

Medline

[36.]

H. Ludwlg, E. Fritz.

Anemia of Cancer Patients: Patient Selection and Patient Stratification for Epoietin Treatment.

Semin. OncoL, 25 (1998), pp. 35-38

Medline

[37.]

A. Maraveyas, R. Pettengell.

What is the Role of Erythropoietin in Patients With Solid Tumors?.

Annals Oncol., 9 (1998), pp. 239-241

[38.]

D.W. Miles, O. Fogerty, C.M. Ash, et al.

Received Dose Intensity: A Randomized Trial of weekly Chemotherapy with and without Granulocyte Colony Stimulating Factor in Small-Cell Lung Cancer.

J. Clin. Oncol., 12 (1994), pp. 77-82

http://dx.doi.org/10.1200/jco.1994.12.1.77 | Medline

[39.]

C.B. Miller, S.R. Mills.

Anemia Associated With Cisplatin Chemotherapy.

Erythropoietin Molecular Physiology and clinical applications, pp. 299-308

[40.]

K. Mori, Y. Saitoh, K. Tominaga.

Recombinant Human Granulocyte Colony-Stimulating Factor in Patients Receiving Intensive Chemotherapy for Non Small Cell Lung Cancer.

Eur. J. Cancer, 29 A (1993), pp. 677-680

[41.]

M.R. Nowrousian, V. Essers, R. Voigtmann, W. Gallaschw.

Pathophysiology of Cancer-Related Anemia.

Rherythropoietin in Cancer Supportive Treatment, pp. 13-34

[42.]

C. Oberhoff, B. Neri, D. Amadorl, et al.

Recombinant Human Erythropoietin in the Treatment of Chemotherapy induced Anemia and Prevention of Transfusion Require ment Associated with Solid Tumors: A Randomized, Controlled Study.

Annals Oncol., 9 (1998), pp. 255-260

[43.]

P. Pizzo.

A Drug therapy.

The New England Journal of Medicine, 328 (1993), pp. 1323-1332

http://dx.doi.org/10.1056/NEJM199305063281808 | Medline

[44.]

J.L. Pujol, L. Quantln, F.B. Michel.

Les Facteurs de Croissance Cellulaire dans le Traitement des Cancers Bronchiques.

Rev. Mal Resp., 13 (1996), pp. 335-338

[45.]

R.R. Romanowski, A.J. Syfkowsi.

The Molecular Structure of Human Erithropoietin.

Hem./Onc. Clin. N Am, 8 (1994), pp. 885-894

[46.]

J.P. Sculler, M. Paesmans, G. Bureau, et al.

Multiple drug Weekly Chemotherapy Versus Standard combination regimen in small cell Lung Cancer·a Phase III Randomized Study Conducted by the European Lung Cancer Working Party.

J. Clin. Oncol, II (1993), pp. 1858-1865

[47.]

G.L. Semenza.

Regulation of Erythropoetin Production.

Hem./Onc. Clin. N. Am., 8 (1994), pp. 863-883

[48.]

M.L. Sherman, M.B. Garnick.

Hematopoietic Growth Factors.

The Chemoterapy Source Book, second, pp. 141-154

[49.]

R.L. Souhami, R. Rudd, D.E. Ruiz, M.C. Elvira, et al.

Randomized Trial Comparing Weekly Versus 3-Week Chemotherapy in Small Cell Lung Cancer: a Cancer Research Campaign Trial.

J. Clin. Oncol., 12a (1994), pp. 1806-1813

[50.]

J.L. Spivak.

The Biology and Clinical Applications of Recombinant Erythropoietin.

Semin Oncol, 25 (1998), pp. 7-11

Medline

[51.]

W.P. Steward, J. Von Powel, V. Gatzemeler, Woll P. Tatcher, et al.

Effects of Granulocyte Macroghage Colony-Stimulating Factor and Dose Intensification of V-ICE Chemotherapy in Small-Cell Lung Cancer: A Prospective Randomized Study of 300 Patients.

J. Clin. Oncol, 16 (1998), pp. 642-650

http://dx.doi.org/10.1200/jco.1998.16.2.642 | Medline

[52.]

N. Thatcher, S.M. Lee, P.J. Woll, M. Middleton, H. Anderson, P. Burt, P. Stout.

Dose intensity in small cell lung cancer.

Sem. Oncol., 25 (1998), pp. 12-18

[53.]

N. Thatcher.

Predicting the Response to R-HuEPO in Anemia Cancer Patients Undergoing Chemotherapy.

Erythropoiesis, 6 (1996), pp. 99-106

[54.]

V.C.Q. Tjan-Heijnen, B. Biesma, J. Festen, T.A.W. Splinter, A. Cox, D.J.T. Wagner, P.E. Postmus.

Enhanced Myelotoxicity due to Granulocyte Colony Stimulating Factors Administration until48 hours before the next Chemotherapy Course in Patients with Small-Cell Lung Carcinoma.

Clin. One., 6 (1998), pp. 2708-2714

[55.]

V. Trillet-Lenolr, J. Green, C. Manegold, J. Non Pawel, V. Gatzmeier, et al.

Recombinant Granulocyte Colony Stimulating Factor Reduces the Infections Complications of Cytotoxic Chemotherapy.

Eur. J. Cancer, 29 (1993), pp. 319-324

[56.]

N. Tsuruta, et al.

Granulocyte-macrophage-colony stimulating factor stimulates tumor invasiveness in squamous cell lung carcinoma.

Cancer., 82 (1998), pp. 2173-2183

Medline

[57.]

T. Urban, M.P. Schuller, B. Lebeau.